The ship we send

into the signal,

returns at dawn.

PCAC does NOT recommend Category 1 (unrestricted compounding) for BPC-157 at the 2026-07-23 meeting; outcome is Category 2 return, deferral, or partial/conditional status short of full Cat 1

Regulator agent dominates regulatory decisions. FDA default on unapproved peptides without US safety dossier = not-Cat-1. Counter-narrative ~30%: split decision or conditional Cat 1. Deep-read of OnHealthcare analysis not yet done; could shift +/-10 pts.

At least 2 of the 4 peptides reviewed at the 2026-07-23 PCAC meeting (BPC-157, KPV, MOTs-C, TB-500) receive a Category 1 or conditional Category 1 recommendation

REVISION to prior forecast. 12-peptide Cat 2 removal wave Apr 15 is a much more aggressive reclassification trajectory than anticipated. Original 0.70 not-Cat-1 forecast for BPC-157 alone still holds, but broadened basket (any 2 of 4) makes at-least-one-Cat-1 meaningfully more likely. Counter-narrative ~45%: safety dossiers still weak for all four; PCAC defers to additional review session. Compounding pharmacy lobby organized but without FDA-approvable safety data, caution wins.

By 2026-07-31, The Compound has at least two peptide-adjacent properties live on production domains (comparison site, safety tool, skincare comparison, tracker app, or regulatory tracker)

Tests the AI-speed-portfolio build thesis. If we cannot ship 2 properties in 103 days at AI speed, the underlying operating hypothesis needs revision. Counter-narrative ~25%: ship-one-focused beats ship-many-parallel; regulatory shift delays validate deferral; Iacob's attention fragments across Crown Years and other projects.

CMS reports fewer than 1,000,000 Medicare GLP-1 Bridge enrollees by 2026-12-31 (per official CMS Part D enrollment data)

Base rate: new Medicare Part D programs enroll slowly in year one (10-15% of eligible). 1M = ~7% of 14M eligible. Launches July 1 2026, so only 6 months of enrollment window in 2026. Friction factors: physician re-prescribing, formulary navigation, step therapy. Counter-narrative ~35%: aggressive CMS outreach + pent-up demand drives faster-than-normal uptake. Resolves on CMS public enrollment data release (usually Q1 following year).

By 2026-12-31, peptide vendor affiliate revenue is less than 30 percent of total The Compound affiliate revenue (i.e., GLP-1 telehealth remains dominant revenue stream)

Math dominates: peptide affiliate CPA is 10-30x lower than GLP-1 affiliate CPA. Even if peptide traffic matches GLP-1 traffic, revenue share remains minority. Counter-narrative ~15%: PCAC grants Cat 1 (30% chance per prior forecast) + major US pharma launches approved peptide product with affiliate program + Compound pivots heavily. Resolves on The Compound internal Katalys + peptide network payout data. | OPERATOR 2026-04-23: Foundayo FDA-approved 2026-04-01; Hims listing it at $25/mo insurance / $149 cash — branded-GLP-1 economics more entrenched, marginally strengthens 0.85.

By 2026-12-31, Hims and Hers publicly launches a compounded peptide DTC offering (BPC-157, GHK-Cu, or TB-500) through its telehealth platform

Hims acquired the facility 14 months ago for exactly this. Business-line extensions typically launch within 18-24 months of M&A. Reclassification gives political cover. Counter-narrative ~20%: regulatory setback at July PCAC forces Hims to delay to 2027; safety incident in industry triggers pre-launch freeze. | OPERATOR 2026-04-23: Foundayo (Lilly orforglipron, FDA-approved 2026-04-01) now distributed via Hims at $25/mo insurance / $149 cash alongside Wegovy pill — confirms Hims-as-channel-for-every-approved-GLP-1 thesis. Active behavioral pattern: in Feb 2026 Hims sold a compounded copy of the first GLP-1 pill 2 months post-approval; FDA forced retreat within weeks. Treat as reinforcing 0.83 with retreat-under-enforcement as a latent cap on unrestricted launch timing.

By 2027-03-31, a top-5 US news outlet (NYT, WSJ, CNN, NPR, WaPo) publishes a major feature on peptide injuries, contamination, or deaths sourced from compounded/gray-market products

Adoption at current velocity plus 40 percent contamination rate plus minimal regulation equals statistical certainty of adverse event. Media narrative arc typically runs hype-phase to backlash-phase within 12-18 months. Already have safety-focused coverage seeding (NPR Feb 2026, UNSW April 2026). Counter-narrative ~30%: FDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident; industry self-regulation via compounders catches contamination early.